ResearcherPurdue University West LafayetteActive in the last 2 years
Masahiro Murakami
Matched on ORCID iD 0000-0001-7816-8311; OpenAlex author ID A5070225790, A5126348179. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 6
- Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027). Co-author DOI 10.1371/journal.pone.0345459↗
- Sclerosing encapsulating peritonitis in a dog with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12917-022-03485-0↗
- Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadj… Co-author DOI 10.1186/s13063-021-05541-w↗
- [Endoscopic Stent Placement to Alleviate Afferent Loop Syndrome Following Recurrence of Pancreatic Cancer]. Co-author PMID 28133265↗
- [Analysis of portal vein resection during pancreaticoduodenectomy in patients with pancreatic cancer]. Co-author PMID 25731461↗
- [Bypass surgery or stent placement for biliary obstruction in patients with unresectable pancreatic cancer]. Co-author PMID 24393895↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Masahiro Tanemura · 2 shared papers, 2021–2026 · strength 0.32
- Paper Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resec… DOI 10.1371/journal.pone.0345459↗
- Paper Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound … DOI 10.1186/s13063-021-05541-w↗
- Tadafumi Asaoka · 2 shared papers, 2021–2026 · strength 0.32
- Paper Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resec… DOI 10.1371/journal.pone.0345459↗
- Paper Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound … DOI 10.1186/s13063-021-05541-w↗
- Yuichiro Doki · 2 shared papers, 2021–2026 · strength 0.32
- Paper Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resec… DOI 10.1371/journal.pone.0345459↗
- Paper Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound … DOI 10.1186/s13063-021-05541-w↗
- Masanori Tsujie · 2 shared papers, 2021–2026 · strength 0.32
- Paper Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resec… DOI 10.1371/journal.pone.0345459↗
- Paper Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound … DOI 10.1186/s13063-021-05541-w↗
- Hidetoshi Eguchi · 2 shared papers, 2021–2026 · strength 0.32
- Paper Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resec… DOI 10.1371/journal.pone.0345459↗
- Paper Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound … DOI 10.1186/s13063-021-05541-w↗
- Hirofumi Akita · 2 shared papers, 2021–2026 · strength 0.32
- Paper Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resec… DOI 10.1371/journal.pone.0345459↗
- Paper Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound … DOI 10.1186/s13063-021-05541-w↗
- Chikato Koga · 2 shared papers, 2016–2026 · strength 0.27
- Yoshifumi Iwagami · 1 shared paper, 2026 · strength 0.22
- Yoshito Tomimaru · 1 shared paper, 2026 · strength 0.22
- Hiroshi Wada · 1 shared paper, 2026 · strength 0.22
- Yoshiteru Katsura · 1 shared paper, 2026 · strength 0.22
- Atsushi Tsukamoto · 1 shared paper, 2022 · strength 0.20
- Yusuke Tsukada · 1 shared paper, 2022 · strength 0.20
- Junichi Hasegawa · 3 shared papers, 2013–2016 · strength 0.12
- Paper [Endoscopic Stent Placement to Alleviate Afferent Loop Syndrome Following Recurrence of Pancreatic Cancer]. PMID 28133265↗
- Paper [Analysis of portal vein resection during pancreaticoduodenectomy in patients with pancreatic cancer]. PMID 25731461↗
- Paper [Bypass surgery or stent placement for biliary obstruction in patients with unresectable pancreatic cancer]. PMID 24393895↗
- Osakuni Morimoto · 1 shared paper, 2021 · strength 0.10
- Daisaku Yamada · 1 shared paper, 2021 · strength 0.10
- Yutaka Takeda · 1 shared paper, 2021 · strength 0.10
- Hidenori Takahashi · 1 shared paper, 2021 · strength 0.10
- Motohiro Hirao · 2 shared papers, 2013–2016 · strength 0.08
- Riichiro Nezu · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.